Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share (the "Shares")
-
Shares outstanding
-
66.2M
-
Number of holders
-
31
-
Total shares
-
19.3M
-
Shares change
-
+14.3M
-
Total reported value, excl. options
-
$109M
-
Value change
-
+$80.7M
-
Number of buys
-
21
-
Number of sells
-
-8
-
Price
-
$5.65
Significant Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value per share (the "Shares") (LYRA) as of Q2 2022
31 filings reported holding LYRA - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value per share (the "Shares") as of Q2 2022.
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value per share (the "Shares") (LYRA) has 31 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.3M shares
of 66.2M outstanding shares and own 29.12% of the company stock.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (9.15M shares), PURA VIDA INVESTMENTS, LLC (2.58M shares), Nantahala Capital Management, LLC (2.37M shares), Samsara BioCapital, LLC (1.78M shares), VR Adviser, LLC (924K shares), VANGUARD GROUP INC (676K shares), Soleus Capital Management, L.P. (592K shares), Ikarian Capital, LLC (347K shares), GEODE CAPITAL MANAGEMENT, LLC (120K shares), and Clearline Capital LP (119K shares).
This table shows the top 31 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.